Cancer Treatment Today

The NeoTYPE Myeloid Disorders Profile is a 54 gene panel that targets known mutations associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Testing using this panel can aid in making therapy decisions, predicting prognosis, and can be used in clinical research.

In this situation, there was already a diagnosis of a myeloproliferative disorder, with JAK2 being +. BCR/ABL was negative, ruling out CML. The use f this profile is investigtioanl to make diagnoses of specific disorders. This is a proprietary panel and its performance as a diagnostic tool is not securely determined. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories.

The NeoTYPE MPN Profile provides complete testing to identify mutations associated with the myeloproliferative neoplasms polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The combination of genes tested in this Profile can be used to differentiate reactive conditions from MPN, classify disease, assess prognosis, and identify clinical trial opportunities for novel therapies. The use f this profile investigational to make diagnoses of specific disorders. Thisi i a proprietary panel and its performance as a diagnostic tool is not securely determined. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories.
Frank C. Kuo, l Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms. Current Hematologic Malignancy Reports June 2015, Volume 10, Issue 2,  pp 104–111| Cite as
Chng, Wee-Joo et al, Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. Journal of Clinical Pathology (2016)